Introduction {#sec1_1}
============

Lung cancer is one of the commonest cancers worldwide and the leading cause of cancer deaths. The presence of targetable epidermal growth factor receptor (EGFR) mutations in the tumour has allowed for the use of tailored treatments like tyrosine kinase inhibitors (TKIs) to significantly prolong survival in some patients. In East Asia, the prevalence of these mutations is around 38.4% in non-small cell lung carcinoma (NSCLC) \[[@B1]\].

Circulating tumour DNA (ctDNA) are tumour-specific DNA fragments that are shed into the blood stream. Its presence provides an opportunity to use non-invasive blood biomarkers to detect mutations, including EGFR. Multiplex PCR or next-generation sequencing (NGS) based platforms are available to detect ctDNA. Recently, this technology has been approved by regulators for use in diagnosis, guiding treatment, and monitoring emergence of resistant mutations in metastatic NSCLC \[[@B2], [@B3]\]. Some groups have also proposed monitoring the plasma EGFR ctDNA levels for dynamic changes to predict treatment failure of TKIs \[[@B4], [@B5], [@B6]\].

In stage I--III NSCLC, the use of ctDNA in these group of patients is still experimental. In surgical series, it has been suggested that ctDNA could be used to detect minimal residual disease and predict early recurrences \[[@B7], [@B8], [@B9], [@B10]\]. There is limited evidence that ctDNA could be used to monitor patients who have undergone radiotherapy \[[@B8], [@B11]\].

After radical lung radiotherapy, a portion of patients may suffer high-grade treatment-related toxicities and a significant proportion will still relapse despite this. The interpretation of radiological changes after radiotherapy is also complicated by infective or inflammatory changes, scarring and fibrosis resulting in delayed diagnosis. There is thus an unmet need for a non-invasive biomarker that could allow clinicians to prognosticate and predict for treatment failures in these patients.

Our primary aim of this study was to evaluate the use of baseline plasma EGFR ctDNA in a cohort of EGFR mutant patients undergoing radical lung radiotherapy. We hypothesised that patients with a detectable pre-treatment plasma EGFR ctDNA would reach a higher disease stage, which may correlate with a poorer survival outcome than in those without.

Case Presentation {#sec1_2}
=================

Patients {#sec2_1}
--------

We conducted a pilot prospective cohort study from April 2017 to August 2018 in the National Cancer Centre Singapore for patients referred to the radiotherapy department for radical lung radiotherapy. The protocol and consent forms were reviewed and approved by SingHealth Institution Review Board. All patients were required to sign informed consent prior to enrolment. The participants had to be fully staged with PET/CT, MRI brain, and EBUS before recruitment. Only radically treatable stage I--III lung adenocarcinoma with a biopsy-proven targetable EGFR mutation in exons 18--21 \[[@B11]\] were recruited. Patients were recruited consecutively. Prior use of chemotherapy was not an exclusion criteria.

Plasma EGFR Mutation ctDNA Procedure {#sec2_2}
------------------------------------

Twenty millilitres of blood (4 EDTA tubes) were collected at CT-simulation scans, prior to radiotherapy, for measurement of baseline test. The blood collected was processed within 2 h and stored for ctDNA extraction. Detection of plasma EGFR mutations, including p.E746_A750del, p.L858R, and p.T790M, was conducted by amplification refractory mutation system (ARMS) PCR. Laboratory staff were blinded to patient and tumour details to avoid read-out bias of PCR results. A second test was planned 1 month after radiotherapy. The results of the tests were blinded to the treating physician and patient.

The protocol was later amended to allow for use of multi gene panel (gene list: *ALK*, *BRAF*, *ERBB2*, *EGFR* \[exons 18--21\], *KRAS*, *MET*, *NRAS*, *PIK3CA*, *STK11*, and *TP53*) NGS LiquidMARK^TM^ test \[[@B12]\] on the stored frozen plasma samples.

Baseline and Follow-Up Evaluation {#sec2_3}
---------------------------------

The patient\'s characteristics, tumour details and, treatment plans were recorded at baseline, and treatment outcomes (local or distant relapses) were recorded at the 3--4 monthly follow-up. Survival outcomes were recorded from time of blood taking to event or last follow-up visit. Patients lost to follow-up would be censored at last visit. Patient who did not complete the radical treatment would not be assessed for outcome studies.

Statistics {#sec2_4}
----------

Baseline characteristics of patients were compared with plasma EGFR ctDNA detection rate, these were also compared against relapse/death outcomes. We used χ^2^ test for categorical data and the *t* test for continuous data. Time to event was taken from the start of radiotherapy. Kaplan-Meier method was used to detect the differences between survival outcomes. The impact of plasma EGFR ctDNA test results on survival outcomes was evaluated by log-rank test. *p* values are two-tailed and those below 0.05 were considered statistically significant. Statistical analysis was conducted using IBM SPSS statistics ver. 25.

Results {#sec1_3}
=======

Patient Characteristics {#sec2_5}
-----------------------

During the trial enrolment period, 9 patients consented to the study. Patient and tumour characteristics are summarised in Table [1](#T1){ref-type="table"}. One patient subsequently declined radiotherapy and was lost to follow-up. This patient was excluded from outcome analysis. Eight underwent radical lung radiotherapy (3 SBRT, 5 chemo-radiotherapy).

Plasma EGFR ctDNA Test Results {#sec2_6}
------------------------------

Two of 9 (22.2%) participants had detectable results at baseline using ARMS PCR. In combining this with NGS, 4 of 9 (44.4%) participants had detectable ctDNA (3 EGFR and 1 TP53 mutations) at baseline. The 3 patients who had a detectable baseline plasma EGFR ctDNA had stage IIIA/C disease at diagnosis. None of the 4 stage I/II patients had a detectable plasma EGFR ctDNA result. The sensitivity of tests in detecting plasma EGFR ctDNA in stage III was 60% versus 0% in stage I/II patients, although this result was not statistically significant. No patient and tumour variable studied had a significant correlation with baseline plasma EGFR ctDNA detection (Table [2](#T2){ref-type="table"}). Only 1 patient did a 1-month post-treatment test.

Survival Data {#sec2_7}
-------------

Of the 8 patients who completed radical radiotherapy, the overall median duration follow-up was 396 days (212--514 days). At last follow-up, 6 patients remained disease free and 2 patients had distant metastatic relapse, of which 1 passed away subsequently. The latter had detectable plasma EGFR ctDNA at 1 month post-treatment and had radiological metastatic disease progression 48 days after.

On analysis, patients with a detectable baseline plasma EGFR ctDNA detection were associated with relapse/death outcome (*p* = 0.01) (Table [3](#T3){ref-type="table"}). These patients also had a shorter median PFS (155 days vs. NR, *p* = 0.004), although OS was not significantly different (404 days vs. NR; *p* = 0.083) from the patients with a negative test result (shown in Fig. [1](#F1){ref-type="fig"}).

Discussion {#sec1_4}
==========

Our study was conducted as a prospective pilot study to test for plasma EGFR ctDNA in patients with early and locally advanced staged lung adenocarcinoma with biopsy-proven EGFR mutations. These patients underwent initial plasma EGFR ctDNA testing with ARMS PCR followed by radical radiotherapy. The trial was terminated as the investigators felt it was futile to continue due to poor recruitment and low plasma EGFR ctDNA detection rates. The protocol was updated after recruitment was stopped to allow for the retrospective use of NGS for better sensitivity \[[@B13]\] and detection of other ctDNA. This improved the overall detection rate of ctDNA from 22.2 to 44.4%.

The ctDNA studies performed in early-stage NSCLC have reported poor detection rates \[[@B7], [@B9], [@B10], [@B14], [@B15]\]. Similarly, our detection rate in this early-stage series was poor. We noted that detection rate of plasma EGFR ctDNA was higher in stage III than in stage I/II (60 vs. 0%) disease. Although this difference was not statistically significant, ctDNA detection rates have also been noted to be higher in patients with greater tumour burden \[[@B7], [@B16], [@B17], [@B18]\]. We also studied the difference in mean GTV and SUVmax values between detectable and undetectable patients as surrogates for tumour load and activity, respectively. The results were, however, not significant. We thus would not recommend its use in early-stage disease outside of clinical trials.

In our study, only 1 patient agreed to post-radiotherapy blood test. This patient had completed 33 fractions of concurrent chemo-radiotherapy and had a subsequent decrease in plasma EGFR ctDNA allele frequency at 1 month post-treatment from 1.7 to 0.8%. Unfortunately, he relapsed radiologically at a distal site shortly after the blood test. From previous surgical series, a detectable plasma EGFR ctDNA after radical surgery suggested the presence of molecular/minimal residual disease (MRD). In these series, the persistence of plasma ctDNA identified patients at high risk of relapse and preceded radiological progression by a median of 70 days to 5.2 months \[[@B7], [@B8], [@B10], [@B19], [@B20]\]. This association between post-treatment ctDNA and MRD may apply to radiotherapy patients as well \[[@B8], [@B11]\] and may be useful to complement follow-up radiological scans for diagnosis of relapse.

Univariate analyses of our results showed a negative correlation between a detectable baseline plasma EGFR ctDNA and PFS. This result is consistent with some reports performed in metastatic NSCLC patients \[[@B21], [@B22], [@B23], [@B24], [@B25]\]. Given that ctDNA values are correlated with tumour burden, we speculate that these patients with radiological local disease but detectable baseline plasma EGFR ctDNA may harbour a higher systemic burden and do poorly despite local radical treatment.

Our study is limited due to the small sample size, heterogenous patient cohort and short follow-up period. The interpretation of the NGS technique added later in the protocol could have also resulted in increased false negative results due to ctDNA degradation. However, despite these shortcomings, there are very few studies reporting the use of plasma EGFR ctDNA in non-metastatic NSCLC. Given the poor outcomes of lung cancer patients and difficulties of CT-scan interpretation of post-radical lung radiotherapy, the use of plasma ctDNA could serve as an important biomarker in treatable NSCLC for staging, prognostication, and follow-up.

In conclusion, the clinical applications of ctDNA including plasma EGFR ctDNA in NSCLC patients is evolving. With improved technology and access, the use of non-invasive tests like plasma EGFR ctDNA earlier in the course of disease may be useful to guide future clinical management. The findings of our study suggest that plasma EGFR ctDNA was associated with later-stage disease and may have a negative prognostic value in non-metastatic patients. One patient who had a persistent post-treatment plasma EGFR ctDNA had radiological progression shortly after, possibly indicating some utility for monitoring patient outcomes. These results should be explored in future trials.
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###### 

Patient and tumour characteristics and plasma EGFR ctDNA results and outcomes

  No.   Gender   Age, years   TNM (AJCC 8th ed.)    Histological EGFR                  Prior chemo   ARMS PCR                                                Plasma NGS                                                   GTV, mL          PET SUVmax   Treatment        Post-RT plasma          Outcome
  ----- -------- ------------ --------------------- ---------------------------------- ------------- ------------------------------------------------------- ------------------------------------------------------------ ---------------- ------------ ---------------- ----------------------- -------------------
  1     Female   56.8         cT2aN2M0 Stage IIIA   Exon 21                            No            Exon 21 L858R (1.7%)[\*](#T1F1){ref-type="table-fn"}    Not done                                                     44.9             17.6         Concurrent CRT   Exon 21 L858R (0.18%)   Relapse, dead
                                                                                                                                                                                                                                                                                                 
  2     Male     77.8         cT1aN0M0 Stage IA     Exon 19                            No            Undetectable                                            TP53 c.780del (1.7%)[\*](#T1F1){ref-type="table-fn"}         9                8.9          SBRT             Not done                Alive
                                                                                                                                                                                                                                                                                                 
  3     Male     71.1         CT0N2M0 Stage IIIA    Exon 19 c.2235_49del               No            Undetectable                                            Undetectable                                                 9.2              9.6          Concurrent CRT   Not done                Alive
                                                                                                                                                                                                                                                                                                 
  4     Female   73.9         CT3N0M0 Stage IIB     Exon 19                            Yes           Undetectable                                            Undetectable                                                 124.9            10.8         Concurrent CRT   Not done                Alive
                                                                                                                                                                                                                                                                                                 
  5     Male     69.8         CT3N3M0 Stage IIIC    Exon 21 L858R                      No            Exon 21 L858R (0.34%)[\*](#T1F1){ref-type="table-fn"}   Exon 21 L858R (0.36%)[\*](#T1F1){ref-type="table-fn"}        Not calculated   16.3         Nil              Not done                Lost to follow-up
                                                                                                                                                                                                                                                                                                 
  6     Female   76.4         cT1bN0M0 Stage IA2    Exon 19 delE746-S752insl           No            Undetectable                                            Undetectable                                                 11.6             6.5          SBRT             Not done                Alive
                                                                                                                                                                                                                                                                                                 
  7     Male     79.3         Ct1bN2M0 Stage IIIA   Exon 19 c.2270A\>G; c.2235_49del   Yes           Undetectable                                            Exon 19 c.2270A\>G (48.6%)[\*](#T1F1){ref-type="table-fn"}   12.4             6.2          Sequential CRT   Not done                Relapse, alive
                                                                                                                                                                                                                                                                                                 
  8     Female   79.0         CT3N3M0 Stage IIIC    Exon 21 L858R                      Yes           Undetectable                                            Undetectable                                                 49.1             16.6         Concurrent CRT   Not done                Alive
                                                                                                                                                                                                                                                                                                 
  9     Male     76.8         cT2aN0M0 Stage IB     Exon 19 c.2235_49del               No            Undetectable                                            Undetectable                                                 17.0             6.3          SBRT             Not done                Alive

CRT, chemo-radiotherapy; SBRT, stereotactic body radiotherapy; GTV, gross tumour volume.

\% of cell-free DNA.

###### 

Test for factors on detection of plasma EGFR ctDNA

  Variable                    Plasma EGFR ctDNA   *p* value   
  --------------------------- ------------------- ----------- -----------------------------------------
  Gender                                                      1.00[\*](#T2F1){ref-type="table-fn"}
   Male (*n* = 5)             2                   3           
   Female (*n* = 4)           1                   3           
  Stage                                                       0.167[\*](#T2F1){ref-type="table-fn"}
   III (*n* = 5)              3                   2           
   I/II (*n* = 4)             0                   4           
  Pre-ARMS PCR chemotherapy                                   0.774[\*](#T2F1){ref-type="table-fn"}
   Yes (*n* = 3)              1                   2           
   No (*n* = 6)               2                   4           
  Mean GTV, mL                28.7                36.8        0.759[^\^^](#T2F2){ref-type="table-fn"}
  Mean SUVmax                 13.4                9.8         0.433[^\^^](#T2F2){ref-type="table-fn"}

Fisher\'s exact test.

Welch *t* test.

###### 

Characteristics of participants by outcome (relapse/death)

  Characteristics              Outcome       *p* value    
  ---------------------------- ------------- ------------ ---------------------------------------
  Age, years (SD)              68.0 (15.9)   75.8 (2.9)   0.2[^\^^](#T3F2){ref-type="table-fn"}
  Gender, female               1             3            0.6[\*](#T3F1){ref-type="table-fn"}
  Baseline plasma EGFR ctDNA                              0.01[\*](#T3F1){ref-type="table-fn"}
   Detected                    2             0            
   Undetected                  0             6            
  Stage                                                   0.1[\*](#T3F1){ref-type="table-fn"}
   III                         2             2            
   I/II                        0             4            

Fisher\'s exact test.

Welch *t* test.
